Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Atropine 0.05% trumps 0.01% concentration in slowing myopia progression

28 Jun 2020

Atropine 0.05% has double the efficacy of 0.01% eye drops over 2 years, and the former remains the optimal concentration among atropine concentrations in slowing the progression of myopia, a recent study has shown.

Of the 438 children originally randomized to receive 0.05%, 0.025%, 0.01%, or placebo once daily in both eyes in the Low-Concentration Atropine for Myopia Progression (LAMP) phase I study, 383 (87 percent; aged 4-12 years) with myopia of at least –1.0 dioptre (D) were selected to continue in the extended trial (phase II).

Children in the placebo group (LAMP phase I) were switched to receive 0.05% atropine from the beginning of the second-year follow-up. Those in the 0.05%, 0.025%, and 0.01% atropine groups remained in the same regimen. The investigators measured cycloplegic refraction, axial length (AL), accommodation amplitude, photopic and mesopic pupil diameter, and best-corrected visual acuity at 4-month intervals.

The mean spherical equivalent (SE) over the 2-year period was 0.55±0.86 D in the 0.05% (p=0.015), 0.85±0.73 D in the 0.025% (p<0.001), and 1.12±0.85 D in the 0.01% atropine groups (p=0.02), with mean AL changes of 0.39±0.35 mm (p=0.04), 0.50±0.33 mm (p<0.001), and 0.59±0.38 mm (p=0.10), respectively, over 2 years.

Compared with year 1, the efficacy of 0.05% and 0.025% atropine at year 2 remained similar (p>0.1), while that in the 0.01% concentration improved slightly (p=0.04).

Switching to 0.05% atropine significantly reduced myopia progression for the phase I placebo group (SE change, 0.18 D in year 2 vs 0.82 D in year 1; p<0.001; AL elongated 0.15 mm in year 2 vs 0.43 mm in year 1; p<0.001).

“Accommodation loss and change in pupil size in all concentrations remained similar to the first-year results and were well tolerated,” the investigators noted. “Visual acuity and vision-related quality of life remained unaffected.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.